Randomized Controlled Trial Letter Ppublish 8 citations
PubMed: 37068657 DOI: 10.1016/j.annonc.2023.04.001
Why will there never be a randomized trial for NTRK-rearranged tumors?
Ann Oncol 34(7):626-628
Authors: N Penel, L Lebellec, J-Y Blay
Affiliations
- Department of Medical Oncology, Centre Oscar Lambret, Lille, France; University of Lille, CHU Lille, ULR 2694 - Metrics: Evaluation des technologies de santé et des pratiques médicales, Lille, France.
- Department of Medical Oncology, Centre Oscar Lambret, Lille, France.
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France; Université Claude Bernard, Lyon, France.
MeSH
Neoplasms
Cited by
- Should we be testing for germline and "actionable" mutations in all glioma patients? Neurooncol Pract, 2025
- Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review. Jpn J Clin Oncol, 2025
- Adopting life-cycle HTA: a tumor-agnostic precision oncology index economic evaluation from publicly available reimbursement reviews. Int J Technol Assess Health Care, 2025
- Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer. JCO Precis Oncol, 2025